BioSpace News Archive

Positive Phase 1 results in adult glioma patients supported pediatric brain cancer clinical program—now in pivotal studies

Amneal Pharmaceuticals, Inc. announced its results today for the first quarter ended March 31, 2019.

Varian announced it has signed a strategic cooperation framework agreement with Shandong Cancer Hospital in China, for proton therapy clinical application and research.

Aldeyra Therapeutics, Inc. announced quarter ended March 31, 2019 financial results and provided a corporate update.

Altavant Sciences announced that it has been invited to present at the 2019 Respiratory Innovation Summit being held May 17 in Dallas, TX.

Immunovant announced that it will present the first detailed findings in healthy subjects for IMVT-1401 (formerly RVT-1401) in a poster session at the 2019 American Academy of Neurology (AAN) Annual Meeting, being held May 4-10, 2019, at the Pennsylvania Convention Center in Philadelphia, PA.

Following a comprehensive evaluation by Sykehusbygg HF Norway and regional health authorities, Varian was selected to equip two proton therapy centers in Norway with the ProBeam® multi-room system.

Kala Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2019.

AVEO Oncology reported financial results for the first quarter ended March 31, 2019 and provided a business update.

Bristol-Myers Squibb Company announced the Phase 3 CheckMate -498 trial evaluating Opdivo plus radiation versus temozolomide plus radiation in patients with newly diagnosed O6-methylguanine-DNA methyltransferase-unmethylated glioblastoma multiforme did not meet its primary endpoint of overall survival at final analysis.